Lista de obras -

1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals

A descriptive analysis of transgender participants in phase 1-2a trials of the HIV Vaccine Trials Network (HVTN) in the United States and Peru

scientific article published on 05 June 2019

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk

scientific article published on 01 November 2019

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

artículo científico publicado en 2017

Behavioral risk assessment in HIV Vaccine Trials Network (HVTN) clinical trials: A qualitative study exploring HVTN staff perspectives ⬇️

artículo científico publicado el 13 de julio de 2013

Broadly Neutralizing Antibodies for HIV Prevention

scientific article published on 01 January 2020

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

artículo científico publicado en 2019

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection

scientific article published on 29 January 2020

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

artículo científico publicado en 2013

Engaging Transgender People in NIH-Funded HIV/AIDS Clinical Trials Research

scientific article published on August 2016

HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies

artículo científico publicado en 2015

HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial

artículo científico publicado en 2014

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

artículo científico publicado en 2017

Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination

artículo científico publicado en 2019

Intentions to Use Preexposure Prophylaxis Among Current Phase 2B Preventive HIV-1 Vaccine Efficacy Trial Participants ⬇️

artículo científico publicado el 1 de julio de 2013

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.

artículo científico publicado en 2018

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

artículo científico publicado en 2018

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features

article

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial

artículo científico publicado en 2019

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants

artículo científico publicado en 2016

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

artículo científico publicado en 2017

Sources of racial/ethnic differences in awareness of HIV vaccine trials

artículo científico publicado en 2014

Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial

artículo científico publicado en 2015

The inner foreskin of healthy males at risk of HIV infection harbors epithelial CD4+ CCR5+ cells and has features of an inflamed epidermal barrier

artículo científico publicado en 2014

Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection

artículo científico publicado en 2016

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

artículo científico publicado en 2014

Lista de obras de

1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals

A descriptive analysis of transgender participants in phase 1-2a trials of the HIV Vaccine Trials Network (HVTN) in the United States and Peru

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

Behavioral risk assessment in HIV Vaccine Trials Network (HVTN) clinical trials: A qualitative study exploring HVTN staff perspectives ⬇️

Broadly Neutralizing Antibodies for HIV Prevention

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

Engaging Transgender People in NIH-Funded HIV/AIDS Clinical Trials Research

HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies

HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination

Intentions to Use Preexposure Prophylaxis Among Current Phase 2B Preventive HIV-1 Vaccine Efficacy Trial Participants ⬇️

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

Sources of racial/ethnic differences in awareness of HIV vaccine trials

Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial

The inner foreskin of healthy males at risk of HIV infection harbors epithelial CD4+ CCR5+ cells and has features of an inflamed epidermal barrier

Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection

Use of placebos in Phase 1 preventive HIV vaccine clinical trials